About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients.All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores.TSPO-PET imaging showed significant reductions in microglial activation at six months (p<0.05). NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The U ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced dosing has commenced at Johns Hopkins University (JHU) Autoimmunity Center of Excellence, the third clinical site in its Phase 2 trial evaluating intranasal foralumab for the treatment of non-active ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

文章核心观点 - 公司宣布在耶鲁大学医学院的耶鲁MS中心对新患者进行给药，这是评估鼻内福拉珠单抗治疗非活动性继发性进展型多发性硬化症（na - SPMS）的多中心2期临床试验的一部分，该试验预计2025年底完成 [1][3] 公司进展 - 多中心2期临床试验正在进行，耶鲁MS中心已开始对新患者给药，其他参与招募的中心包括约翰霍普金斯大学、马萨诸塞大学医学中心和布里格姆妇女医院 [1] - 双盲、多中心、安慰剂对照的2期试验预计2025年底完成，所有参与者有机会参加为期6个月的开放标签扩展（OLE）研究，以进一步评估福拉珠单抗的长期安全性、耐受性和持久有效性 [3] 药物信息 - 福拉珠单抗是一种全人抗CD3单克隆抗体，鼻内给药可刺激T调节细胞，在COVID、多发性硬化症患者及健康受试者中观察到调节T细胞功能、抑制炎症的效果 [4][5] - 目前已有10名na - SPMS患者在开放标签的扩大使用（EA）计划中接受给药，所有患者在6个月内病情有所改善或稳定，FDA允许额外20名患者加入该计划 [4] - 鼻内福拉珠单抗正在进行2a期随机、双盲、安慰剂对照、多中心、剂量范围试验 [4] 公司概况 - 公司是临床阶段的生物制药公司，利用变革性药物递送技术开发突破性疗法，其创新的鼻腔给药方法相比静脉给药在疗效、安全性和耐受性方面有潜在优势 [6] - 公司的领先候选药物鼻内福拉珠单抗在研究中显示出良好的安全性和临床反应，其免疫疗法替代途径技术已获专利，多个申请正在审批中，有望实现广泛的产品线应用 [6]

文章核心观点 - 生物技术公司Tiziana Life Sciences宣布其CEO将在第37届年度ROTH会议上进行炉边谈话并主持一对一投资者会议，同时介绍了公司主要候选药物鼻内给药的foralumab的相关情况 [1] 公司动态 - 公司CEO Ivor Elrifi将于2025年3月18日12:00 pm PST / 15:00 pm ET / 19:00 pm GMT进行虚拟炉边谈话，并主持一对一投资者会议，会议于3月16 - 18日在加利福尼亚州丹纳波因特举行 [1][2] - 可联系ROTH代表安排一对一会议，也可在线注册观看网络直播 [2] 候选药物情况 - foralumab是一种完全人源抗CD3单克隆抗体，鼻内给药时可刺激T调节细胞，在非活动性继发性进展型多发性硬化症（na - SPMS）开放标签中期扩大使用（EA）计划中，10名患者用药6个月内疾病均有改善或稳定，FDA允许额外20名患者加入该EA计划 [2] - 鼻内foralumab正在非活动性继发性进展型多发性硬化症患者中进行2a期随机、双盲、安慰剂对照、多中心、剂量范围试验 [2] - foralumab能结合T细胞受体，通过调节T细胞功能抑制炎症，在COVID、多发性硬化症患者及健康受试者中均有此效果 [3] 公司介绍 - Tiziana Life Sciences是临床阶段生物制药公司，利用变革性药物递送技术开发突破性疗法，实现免疫疗法的替代给药途径 [4] - 公司创新的鼻腔给药方法与静脉给药相比，在疗效、安全性和耐受性方面有改善潜力 [4] - 公司主要候选药物鼻内foralumab是目前唯一处于临床开发阶段的完全人源抗CD3单克隆抗体，在研究中显示出良好安全性和临床反应 [4] - 公司免疫疗法替代给药途径技术已获专利，多个申请待批，有望实现广泛的产品线应用 [4]

文章核心观点 - 公司重新符合纳斯达克上市最低出价价格要求，证券将继续在纳斯达克上市，同时介绍了公司主要候选药物鼻内给药的福拉珠单抗的情况 [1][2] 公司合规情况 - 2025年1月29日公司被纳斯达克通知不符合最低出价价格上市规则，因其普通股连续30个工作日收盘价未达1美元或以上 [2] - 公司需连续十个交易日保持最低收盘价1美元或以上以重新合规，于2025年3月12日达成，现已重新符合上市规则5550(a)(2) [2] 福拉珠单抗情况 - 福拉珠单抗是全人抗CD3单克隆抗体，鼻内给药可刺激T调节细胞，在非活动性继发性进展型多发性硬化症（na - SPMS）开放标签扩展准入（EA）项目中，10名患者用药6个月内疾病均有改善或稳定，FDA允许额外20名患者加入该EA项目 [3] - 鼻内福拉珠单抗正在非活动性继发性进展型多发性硬化症患者中进行2a期随机双盲安慰剂对照多中心剂量范围试验，该试验于2023年11月开始筛选患者 [3][4] - 福拉珠单抗结合T细胞受体，通过调节T细胞功能抑制炎症，在COVID、多发性硬化症患者及健康受试者中均有此效果，鼻内抗CD3单克隆抗体免疫调节是治疗神经炎症和神经退行性人类疾病的新途径 [4] 公司概况 - 公司是临床阶段生物制药公司，利用变革性药物递送技术开发突破性疗法，实现免疫疗法替代给药途径 [5] - 公司创新的鼻腔给药方法与静脉给药相比，在疗效、安全性和耐受性方面有改善潜力 [5] - 公司主要候选药物鼻内福拉珠单抗是目前唯一处于临床开发阶段的全人抗CD3单克隆抗体，在研究中显示出良好安全性和临床反应，其免疫疗法替代给药途径技术已获专利，多个申请待批，有望实现广泛管线应用 [5]